Rallybio Corporation has announced a significant corporate action: a one-for-two reverse stock split of its common stock. This decision is part of the preparations for its upcoming merger with Avenzo Therapeutics, Inc. The reverse stock split is set to take effect on November 20, 2026, and aims to streamline the company's share structure ahead of the merger.

The move comes after stockholders approved an amendment to the company’s certificate of incorporation during the Annual Meeting on November 4, 2026. The approved amendment allows for a reverse stock split at a ratio ranging from one-for-two to one-for-nine. The final ratio was mutually agreed upon by Rallybio and Avenzo, resulting in the one-for-two split.

Background

Rallybio Corp, classified under the SIC code 2834 for Pharmaceutical Preparations, is a company focused on developing therapies for rare diseases. The company trades on the Nasdaq under the ticker symbol RLYB. Recently, Rallybio has been active in the market, with a series of filings, including a 10-Q and several 8-Ks, indicating ongoing corporate activities and developments.

What the Filing Says

According to the SEC filing dated November 10, 2026, "the reverse stock split will reduce the number of issued and outstanding shares from approximately 5.6 million to approximately 2.8 million." The split will not alter the authorized number of shares, and the par value will remain unchanged at $0.0001 per share.

Impact

This reverse stock split is expected to affect all stockholders uniformly. It will not change their percentage interest in the company’s equity, except for those receiving cash for fractional shares. The move is part of a broader strategy to enhance the company’s market position as it prepares for the merger, which could influence investor sentiment and stock performance.

What's Next

Following the completion of the reverse stock split, Rallybio plans to change its name to Avenzo Therapeutics, Inc. The company will also begin trading under the new symbol “AVZO” on the Nasdaq Capital Market. The merger is contingent upon satisfying Nasdaq’s approval and other closing conditions, which are yet to be detailed in the filings.

For further details, the company has attached a press release as Exhibit 99.1 in the filing, providing additional insights into the reverse stock split and its implications.